Striving to revolutionize the world of pain management
Striving to revolutionize the world of pain management
Striving to revolutionize the world of pain management

 

We’re committed to harnessing the power of revolutionary delivery technologies designed to safely and effectively provide therapies to those who need them most. With a passion for patients and a dedication to innovation, SCILEX is lighting the way forward in pain management.

 
Lighting the way forward
Lighting the way forward
Lighting the way forward

Latest
SCILEX news

Scilex Holding Company, a Sorrento Company, Announces Complete Enrollment on Non-Opioid Injectable SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program For Sciatica Pain Management

Scilex Holding Company, a commercial-stage, non-opioid biopharmaceutical pain management company, announced complete enrollment of its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program for its novel, non-opioid, corticosteroid formulation, injectable dexamethasone sodium phosphate viscous gel product for the treatment of lumbosacral radicular pain (sciatica). SP-102 has received Fast Track status from the FDA. Top-line data … Continue reading Scilex Holding Company, a Sorrento Company, Announces Complete Enrollment on Non-Opioid Injectable SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program For Sciatica Pain Management

 

Re-engineering pain management

At SCILEX, we believe that innovation is the path to improving therapeutic outcomes in pain management. We believe our advances in this area are evidence of our tireless dedication to optimizing the patient experience.

X

Share This Page

XS SM MD LG XL